It started as a treatment for Type 2 diabetes. It became the most discussed medication on the planet when patients and clinicians discovered its power to drive significant, sustained weight loss. Now the class of drugs that includes Ozempic, Wegovy, Mounjaro and Zepbound appears to be doing something that nobody originally designed them to do: meaningfully protecting women from breast cancer.
Research presented at the 2026 American Society of Clinical Oncology Annual Meeting and published simultaneously in the journal JCO Oncology Practice has found that women taking GLP-1 receptor agonists were approximately 30% less likely to be diagnosed with breast cancer compared to women who were not on these medications.
The study was not a small observational footnote. It drew on the electronic health records of more than 111,000 women aged between 45 and 80, all with a body mass index of 25 or above, all of whom had undergone breast imaging through the Penn Medicine health system in Pennsylvania over a three-year period ending in mid-2025.
Lead researcher Dr. Elizabeth McDonald, a professor of radiology at the University of Pennsylvania Perelman School of Medicine and a practicing breast radiologist at Penn’s Abramson Cancer Center, assembled a matched comparison group of roughly 30,500 women — pairing GLP-1 users with non-users who shared equivalent profiles across age, race, ethnicity, body mass index, breast density and diabetes status.
The goal was to strip away the confounding variables and see whether the drug association survived scrutiny. It did. In the matched cohort, about 1.62% of women on GLP-1 medications were diagnosed with breast cancer during the study window, against 2.31% of those not on the drugs — a difference that translates to roughly seven fewer cancers per thousand women.
The biological explanation is still being constructed. GLP-1 drugs work primarily by mimicking a gut hormone that regulates blood sugar, dulls appetite, and slows the digestive process. But their downstream effects appear to extend well beyond glycemic control.
Researchers believe the drugs may reduce chronic inflammation, alter hormonal pathways tied to estrogen-sensitive tumors, and change the metabolic environment in fat tissue — all factors that influence breast cancer development. Excess weight is one of the few known modifiable risk factors for breast cancer, and these drugs attack it on multiple fronts simultaneously.
Dr. McDonald has been careful not to overreach. The study is retrospective and observational — it cannot by itself establish that GLP-1 drugs are causing cancer reduction. But she has noted that if the association is confirmed in a prospective clinical trial, which her team has already announced is underway, the magnitude of protection would be broadly comparable to established preventive interventions such as anti-estrogen therapies — tools that come with significant side effect burdens of their own.
For women already prescribed these medications for weight management or diabetes, the finding reframes the entire conversation around their prescription.
A drug taken to address one problem may be quietly, concurrently, defending against another. The full dimensions of what GLP-1 drugs are capable of are still being uncovered, study by study, year by year. What emerged from the ASCO stage last week is one of the most significant signals yet.